Objectives: Our study examined the impact of adherence to novel oral anticoagulants
[NOACs-dabigatran and rivaroxaban] on ischemic-stroke (IS), major-bleeding (MB), deep …

Background In comparison to warfarin, non–vitamin K antagonist oral anticoagulants (NOAC
s) have the advantages of ease of dosing, fewer drug interactions, and lack of need for …

Background The direct oral anticoagulants (DOACs) reduce the risk of stroke in moderate to
high-risk patients with non-valvular atrial fibrillation (AF). Yet, concerns remain regarding its …

BACKGROUND: Few studies have assessed adherence to non-vitamin K antagonist oral
anticoagulants (NOACs), especially using contemporary data now that multiple NOACs are …

BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are widely used for
prevention of stroke secondary to nonvalvular atrial fibrillation (NVAF). Increased use of …

Abstract Background Direct oral anticoagulants (DOACs) are widely used for stroke
prevention in patients with non-valvular atrial fibrillation (NVAF). We investigated the …

Introduction Medications cannot exert their effect if not taken as prescribed by patients. Our
objective was to summarise the observational evidence on adherence to oral anticoagulants …

Due to a rapid decline of protective anticoagulation with novel oral anticoagulants (NOACs)
when doses are omitted, a high degree medication adherence to NOACs is essential for …

Background: Real-world evidence from published observational studies of adherence to
Novel Oral Anticoagulants (NOACs) medications and associated clinical outcome events in …

Abstract Purpose Direct oral anticoagulants (DOACs) have been promoted in patients with
nonvalvular atrial fibrillation (nv‐AF) as a more convenient alternative to vitamin K …